NEW YORK, NY / ACCESSWIRE / September 5, 2017 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Otonomy, Inc. ("Otonomy" or the "Company") (NASDAQ: OTIC).
On August 30, 2017, Otonomy announced that its Phase 3 clinical trial of OTIVIDEX in patients with Ménière's disease missed its primary endpoint. The Company also announced an immediate suspension of all development activities for OTIVIDEX. According to Reuters, in a webcast earlier today the company said, "At this point, we have no explanation for the unequivocal negative result."
On this news, Otonomy's share price declined.
If you invested in Otonomy stock or options and would like to discuss your legal rights, click here:www.faruqilaw.com/OTIC. There is no cost or obligation to you.
You can also contact us by calling Richard Gonnello toll free at877-247-4292 or at 212-983-9330 or by sending an e-mail torgonnello@faruqilaw.com.
CONTACT:
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
SOURCE: Faruqi & Faruqi, LLP
